Advertisement

Ads Placeholder
Loading...

Valerio Therapeutics SA

ALVIO.PAEURONEXT
Healthcare
Biotechnology
0.12
0.002(1.24%)
U.S. Market opens in 56h 5m

Valerio Therapeutics SA (ALVIO.PA) Stock Competitors & Peer Comparison

See (ALVIO.PA) competitors and their performances in Stock Market.

Peer Comparison Table: Biotechnology Industry

Detailed financial metrics including price, market cap, P/E ratio, and more.

SymbolPriceChange %Market CapP/E RatioEPSDividend Yield
ALVIO.PA€0.12+1.24%42.8M-1.36-€0.09N/A
UCB.BR€264.50-1.23%50.4B32.94€8.03+0.45%
ARGX.BR€647.20+0.22%40.1B38.25€16.92N/A
TUB.BR€219.50+0.69%9.8B104.52€2.10+0.41%
ABVX.PA€101.40-0.59%8B-20.99-€4.83N/A
GLPG.AS€25.60-1.31%1.7B5.28€4.85N/A
NANO.PA€27.40-5.35%1.3B-54.80-€0.50N/A
PHARM.AS€1.43-1.78%998.4M-143.30-€0.01N/A
MEDCL.PA€23.10-0.69%829.4M-37.87-€0.61N/A
IVA.PA€4.72+3.17%656.4M-2.48-€1.90N/A
1

Stock Comparison

Select a stock to compare (requires JavaScript). Showing default comparison.

ALVIO.PA vs UCB.BR Comparison April 2026

ALVIO.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALVIO.PA stands at 42.8M. In comparison, UCB.BR has a market cap of 50.4B. Regarding current trading prices, ALVIO.PA is priced at €0.12, while UCB.BR trades at €264.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALVIO.PA currently has a P/E ratio of -1.36, whereas UCB.BR's P/E ratio is 32.94. In terms of profitability, ALVIO.PA's ROE is +1.46%, compared to UCB.BR's ROE of +0.15%. Regarding short-term risk, ALVIO.PA is more volatile compared to UCB.BR. This indicates potentially higher risk in terms of short-term price fluctuations for ALVIO.PA.Check UCB.BR's competition here

Stock price comparison of stocks in the Healthcare Sector

Loading...

Frequently Asked Questions